期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗复发难治性套细胞淋巴瘤的研究进展 被引量：1

Research progress of bortezomib therapy in patients with relapsed or refractory mantle celllymphoma
原文传递
导出
摘要 复发难治性套细胞淋巴瘤（MCL）的治疗是临床医师面临的严峻挑战。近年来，蛋白酶体抑制剂硼替佐米的应用给复发难治性MCL患者的治疗提供了新方法。就硼替佐米治疗复发难治性MCL的机制、临床疗效以及MCL细胞对硼替佐米耐药产生的机制和应对策略进行综述。 Currently refractory and relapsed mantle cell lymphoma [NILL） conunues to aeveiope a poor prognosis, and the treatment remains a significant clinical challenge. The use of bortezomib in clinic provides a novel method for the treatment of refractory and relapsed MCL. This review summarizes the mechanism and efficiency of bortezomib in the treatment of MCL and the strategies for overcome of bortezomib resistance.
作者 丁洋 王晓萌 综述 常英军 审校
机构地区 河北医科大学第三医院病理科 血液内科
出处 《白血病．淋巴瘤》 CAS 2011年第5期314-316,共3页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 膜细胞 硼替佐米 治疗 Lymphoma, mantle-cell Bortezomib Therapy
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1O'Connor OA. Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. Hematology Am Soc Hematol Educ Program, 2007: 270-276.
  • 2Obrador-Hevia A, Fernandez de Mattos S, Villalonga P, el al. Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies. Blood Rev, 2009, 23: 205-216.
  • 3Hess G, Herbreeht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol, 2009, 27: 3822-3829.
  • 4Goy A, Bernstein SH, Kaht BS, et al. Bortezomib in patients wilh relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the muhicenter phase 2 PINNACLE study. Ann Oncol, 2009, 20: 520-525.
  • 5Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol, 2009, 146: 652-655.
  • 6Goy A, Younes A, MeLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oneol, 2005, 23: 667-675.
  • 7Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, 2011.
  • 8Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol, 2006, 24: 2105-2112.
  • 9Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia, 2008, 22: 179-185.
  • 10Perez-Galan P, Roue G, Villamor N, et al. The protea.some inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107: 257-264.

同被引文献8

  • 1Hoster E, Dreyling M, Klapper W, et al. A new prngnostic index(MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 2008, 111: 558-565.
  • 2Milier AB, Hoogstralen B, Staguet M, et aL Reporting results of cancer treatment. Cancer, 1981, 47: 207.
  • 3Galimberti S, Petrini M. Temisrolimus in treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Manag Res, 2010, 2: 181-159.
  • 4Wang L, Shi W, Wu ZY, et al. Cytostatic ang anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol, 2010, 3: 30-36.
  • 5Ruan J, Martin P, Coleman M, et al. Durable responses with the metronmic reginmen RT-PEPC in elderly patients with recurrent mantle cell lymphoma. Cancer, 2010, 116: 2655-2664.
  • 6Dreyling W, Hoster E, Bea S, et al. Update on the molecular phathogenesis and cinical treatment of mmltle cell lymphoma(MCL): minutes of the 9th European MCL Network Confenrence. Leukemia Lymphoma, 2010, 51: 1612-1622.
  • 7邱录贵.高度侵袭性非霍奇金淋巴瘤的规范化治疗[J].白血病．淋巴瘤,2010,19(8):452-456. 被引量：6
  • 8苏基滢,常春康.套细胞淋巴瘤[J].癌症进展,2011,9(4):414-419. 被引量：7

引证文献1

二级引证文献1

白血病．淋巴瘤
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部